Clinical Effects of Budegraf Inhalation Aerosol and Tiotropium Bromide Combined with Formoterol in the Treatment of Patients at High Risk for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Objective To compare the clinical effectiveness of budesonide inhalation aerosol with tiotropium bromide in combination with formoterol in the treatment of patients at high risk for acute exacerbations of chronic obstructive pulmonary disease(COPD).Methods The clinical data of 100 patients with high risk of acute exacerbation of COPD admitted to Shanghai Yangpu District Kongjiang Hospital from January 2023 to January 2024 were retrospectively se-lected.They were divided into two groups according to different treatment methods,50 cases in each group,the dual group was treated with tiotropium bromide combined with formoterol,and the triple group was treated with budesonide inhalation aerosol.The number of acute exacerbations,6 minute walking test(6MWT),lung function level and blood gas indexes were compared between the two groups.Results After treatment,the number of acute exacerbations in the triple group was(2.23±0.69)times per year,which was less than(4.17±1.10)times per year in the dual group,and the 6MWT in the triple group was(423.47±39.56)m,which was longer than(369.69±41.48)m in the dual group,and the differences were statistically significant(t=10.564,6.634,both P<0.05).The lung function level and blood gas indexes of the triple group were better than those of the dual group,and the differences were statistically significant(all P<0.05).Conclusion In the treatment of patients at high risk for acute exacerbations of COPD,boudigrafin inhalation aerosol was more effective in reducing the number of acute exacerbations,enhancing exercise tolerance and lung func-tion,and improving blood gas indices compared with tiotropium bromide in combination with formoterol.
NETL
NSTL
万方数据
